Global Liposome Development Service 麻豆原创 Research Report 2025

Publication ID:

PB503252142

Publication Date:

March 18, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Liposome Development Service was valued at US$ 1217 million in the year 2024 and is projected to reach a revised size of US$ 2079 million by 2031, growing at a CAGR of 8.1% during the forecast period.
Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.
麻豆原创 Driver
The liposome development service market is driven by the growing demand for advanced drug delivery systems that enhance the bioavailability, efficacy, and safety of therapeutics. Liposomes, being biocompatible and capable of targeted drug delivery, are increasingly used in the development of treatments for cancer, infectious diseases, and vaccines. Additionally, the rise in biologics and personalized medicine, coupled with advancements in nanotechnology, supports the growth of the liposome development service market.
麻豆原创 Challenge
Despite its potential, the liposome development service market faces challenges such as high production costs and complex manufacturing processes that require specialized expertise and facilities. Regulatory hurdles in the approval of liposome-based therapies and the potential for stability issues during storage and transportation further constrain the market's growth. These factors create barriers, particularly for smaller companies with limited resources.
Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.
This report aims to provide a comprehensive presentation of the global market for Liposome Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Development Service.
The Liposome Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Liposome Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposome Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles
Segment by Type
Liposomes
Lipid Nanoparticles
Segment by Application
Preclinical
Clinical
Commercial
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposome Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Liposome Development Service 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Liposomes
1.2.3 Lipid Nanoparticles
1.3 麻豆原创 by Application
1.3.1 Global Liposome Development Service 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Preclinical
1.3.3 Clinical
1.3.4 Commercial
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Development Service 麻豆原创 Perspective (2020-2031)
2.2 Global Liposome Development Service Growth Trends by Region
2.2.1 Global Liposome Development Service 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Liposome Development Service Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Liposome Development Service Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Liposome Development Service 麻豆原创 Dynamics
2.3.1 Liposome Development Service Industry Trends
2.3.2 Liposome Development Service 麻豆原创 Drivers
2.3.3 Liposome Development Service 麻豆原创 Challenges
2.3.4 Liposome Development Service 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposome Development Service Players by Revenue
3.1.1 Global Top Liposome Development Service Players by Revenue (2020-2025)
3.1.2 Global Liposome Development Service Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Liposome Development Service 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Liposome Development Service Revenue
3.4 Global Liposome Development Service 麻豆原创 Concentration Ratio
3.4.1 Global Liposome Development Service 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposome Development Service Revenue in 2024
3.5 Global Key Players of Liposome Development Service Head office and Area Served
3.6 Global Key Players of Liposome Development Service, Product and Application
3.7 Global Key Players of Liposome Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposome Development Service Breakdown Data by Type
4.1 Global Liposome Development Service Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Liposome Development Service Forecasted 麻豆原创 Size by Type (2026-2031)
5 Liposome Development Service Breakdown Data by Application
5.1 Global Liposome Development Service Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Liposome Development Service Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Liposome Development Service 麻豆原创 Size (2020-2031)
6.2 North America Liposome Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Liposome Development Service 麻豆原创 Size by Country (2020-2025)
6.4 North America Liposome Development Service 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposome Development Service 麻豆原创 Size (2020-2031)
7.2 Europe Liposome Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Liposome Development Service 麻豆原创 Size by Country (2020-2025)
7.4 Europe Liposome Development Service 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposome Development Service 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Liposome Development Service 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Liposome Development Service 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Liposome Development Service 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposome Development Service 麻豆原创 Size (2020-2031)
9.2 Latin America Liposome Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Liposome Development Service 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Liposome Development Service 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposome Development Service 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Liposome Development Service 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Liposome Development Service 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Liposome Development Service 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision NanoSystems
11.1.1 Precision NanoSystems Company Details
11.1.2 Precision NanoSystems Business Overview
11.1.3 Precision NanoSystems Liposome Development Service Introduction
11.1.4 Precision NanoSystems Revenue in Liposome Development Service Business (2020-2025)
11.1.5 Precision NanoSystems Recent Development
11.2 Evonik
11.2.1 Evonik Company Details
11.2.2 Evonik Business Overview
11.2.3 Evonik Liposome Development Service Introduction
11.2.4 Evonik Revenue in Liposome Development Service Business (2020-2025)
11.2.5 Evonik Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Liposome Development Service Introduction
11.3.4 Merck KGaA Revenue in Liposome Development Service Business (2020-2025)
11.3.5 Merck KGaA Recent Development
11.4 Genevant Sciences
11.4.1 Genevant Sciences Company Details
11.4.2 Genevant Sciences Business Overview
11.4.3 Genevant Sciences Liposome Development Service Introduction
11.4.4 Genevant Sciences Revenue in Liposome Development Service Business (2020-2025)
11.4.5 Genevant Sciences Recent Development
11.5 Exelead
11.5.1 Exelead Company Details
11.5.2 Exelead Business Overview
11.5.3 Exelead Liposome Development Service Introduction
11.5.4 Exelead Revenue in Liposome Development Service Business (2020-2025)
11.5.5 Exelead Recent Development
11.6 Avanti Polar Lipids
11.6.1 Avanti Polar Lipids Company Details
11.6.2 Avanti Polar Lipids Business Overview
11.6.3 Avanti Polar Lipids Liposome Development Service Introduction
11.6.4 Avanti Polar Lipids Revenue in Liposome Development Service Business (2020-2025)
11.6.5 Avanti Polar Lipids Recent Development
11.7 Nippon Fine Chemical
11.7.1 Nippon Fine Chemical Company Details
11.7.2 Nippon Fine Chemical Business Overview
11.7.3 Nippon Fine Chemical Liposome Development Service Introduction
11.7.4 Nippon Fine Chemical Revenue in Liposome Development Service Business (2020-2025)
11.7.5 Nippon Fine Chemical Recent Development
11.8 Lipoid
11.8.1 Lipoid Company Details
11.8.2 Lipoid Business Overview
11.8.3 Lipoid Liposome Development Service Introduction
11.8.4 Lipoid Revenue in Liposome Development Service Business (2020-2025)
11.8.5 Lipoid Recent Development
11.9 Polymun Scientific
11.9.1 Polymun Scientific Company Details
11.9.2 Polymun Scientific Business Overview
11.9.3 Polymun Scientific Liposome Development Service Introduction
11.9.4 Polymun Scientific Revenue in Liposome Development Service Business (2020-2025)
11.9.5 Polymun Scientific Recent Development
11.10 Corden Pharma
11.10.1 Corden Pharma Company Details
11.10.2 Corden Pharma Business Overview
11.10.3 Corden Pharma Liposome Development Service Introduction
11.10.4 Corden Pharma Revenue in Liposome Development Service Business (2020-2025)
11.10.5 Corden Pharma Recent Development
11.11 Acuitas Therapeutics
11.11.1 Acuitas Therapeutics Company Details
11.11.2 Acuitas Therapeutics Business Overview
11.11.3 Acuitas Therapeutics Liposome Development Service Introduction
11.11.4 Acuitas Therapeutics Revenue in Liposome Development Service Business (2020-2025)
11.11.5 Acuitas Therapeutics Recent Development
11.12 Creative Biolabs
11.12.1 Creative Biolabs Company Details
11.12.2 Creative Biolabs Business Overview
11.12.3 Creative Biolabs Liposome Development Service Introduction
11.12.4 Creative Biolabs Revenue in Liposome Development Service Business (2020-2025)
11.12.5 Creative Biolabs Recent Development
11.13 Creative Biostructure
11.13.1 Creative Biostructure Company Details
11.13.2 Creative Biostructure Business Overview
11.13.3 Creative Biostructure Liposome Development Service Introduction
11.13.4 Creative Biostructure Revenue in Liposome Development Service Business (2020-2025)
11.13.5 Creative Biostructure Recent Development
11.14 T&T Scientific
11.14.1 T&T Scientific Company Details
11.14.2 T&T Scientific Business Overview
11.14.3 T&T Scientific Liposome Development Service Introduction
11.14.4 T&T Scientific Revenue in Liposome Development Service Business (2020-2025)
11.14.5 T&T Scientific Recent Development
11.15 FormuMax Scientific
11.15.1 FormuMax Scientific Company Details
11.15.2 FormuMax Scientific Business Overview
11.15.3 FormuMax Scientific Liposome Development Service Introduction
11.15.4 FormuMax Scientific Revenue in Liposome Development Service Business (2020-2025)
11.15.5 FormuMax Scientific Recent Development
11.16 PlantaCorp
11.16.1 PlantaCorp Company Details
11.16.2 PlantaCorp Business Overview
11.16.3 PlantaCorp Liposome Development Service Introduction
11.16.4 PlantaCorp Revenue in Liposome Development Service Business (2020-2025)
11.16.5 PlantaCorp Recent Development
11.17 CD Bioparticles
11.17.1 CD Bioparticles Company Details
11.17.2 CD Bioparticles Business Overview
11.17.3 CD Bioparticles Liposome Development Service Introduction
11.17.4 CD Bioparticles Revenue in Liposome Development Service Business (2020-2025)
11.17.5 CD Bioparticles Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.